Page 6 - Indian Pharma Companies

Covid-19 crisis: Bharat Biotech's vaccine gets nod for human trials

The SARS-CoV-2 strain was isolated at National Institute of Virology (Pune), an institute under the ICMR, and transferred to Bharat Biotech.

India's coronavirus drug market set for price war as firms ready launches

Sources say Cipla-BDR's favipiravir will be at least 30 per cent cheaper than Glenmark's price of Rs 103 per tablet. Cipla did not confirm.

Cadila-CSIR's sepsis drug shows promise in fight against Covid-19

The public-private partnership trial-generated data will be soon presented before the country's drug regulator to see if it can get emergency-use authorisation.

Covid-19 crisis: Made-in-India remdesivir may come by end of June

Currently, the drug is allowed for "restricted emergency use" on severely ill hospitalised Covid patients in India.

Maharashtra may procure remdesivir from Bangladesh to treat Covid patients

State government to procure 10,000 vials for Rs 12 crore

Amidst controversy, Indian companies continue to manufacture HCQ

Once touted as a 'wonder drug', HCQ has been battling global controversies around its safety and efficacy as a prophylactic against the new coronavirus SARS-CoV-2.

30 groups in India working on coronavirus vaccine, 20 at 'good pace'

ICMR conducting study on presence of antibodies in people, results next week

India allows export of paracetamol API amid coronavirus outbreak

The Indian government in March put a hold on exports of several drugs including paracetamol to secure supplies for its people after COVID-19 outbreak disrupted the industry's supply chain globally.

Covid-19 lockdown: After April shock, drug sales improve in May

Till May 15, the overall inventory was 39 days, compared to 43 days in first half of the previous month

Huge scope for Indian pharma as FDA eases drug scrutiny over shortage in US

Injectibles account for 60% of crunch; most plants under American regulator's lens the past two months have now received positive outcomes

Antiviral drugs see demand surge in India, but segment declines 5.5%

Data from market research firm AIOCD-AWACS shows that sales of oseltamivir (common brand Tamiflu), used against the influenza virus and also for swine flu, went up by 35.8 per cent in April

Antibiotic sales drive domestic pharma mkt down 11.2% in lockdown-hit April

Sale of anti-infectives (11% of domestic pharma market) fell by 21.5%, while gynaecological and dermatological drugs fell by about 23%

Serum Institute hopes to roll out a Covid-19 vaccine. Is this realistic?

The Pune-based company plans to start trials on people to assess whether the Bacille Calmette-Guerin (BCG) vaccine for tuberculosis can also protect against the Covid-19 virus.

Not just bigwigs, Mid-rung local players join coronavirus vaccine race

With vaccines of some firms already in animal trial phase, developers say that if all goes well, India could have a vaccine by next year

Growth prospects, valuations aid Indian pharma firms surpass foreign MNCs

With the pharma sector being rerated, given steady growth prospects and attractive valuations, all the companies, including pharma MNCs, will see greater investor interest

RPG Life Sciences delivers life-saving drugs directly to patients

Despite the pharmaceutical industry having the essential commodities tag, the administration, police and building societies was not allowing movement of people and products

Covid-19 impact: Pharma players join hands to ensure smooth production

Combined capacity utilisation at all-India level is 60-70% - higher than in most other industries

Coronavirus outbreak: Quick USFDA approvals for asthma drug makers

Cipla gets nod for drug from USFDA earlier than expected; Lupin in fray

Coronavirus outbreak: Pharma market grows 9% in March due to panic buying

Cardio-diabetic and respiratory segments clock robust growth

India lifts curbs on exports of 13 active pharmaceutical ingredients

In the first week of March, India restricted the exports of 13 APIs and their formulations to ensure there was no shortage in the domestic market.